Upload
lenhu
View
214
Download
0
Embed Size (px)
Citation preview
3/27/2017
1
Derm Drugs:The Price is Too Darn High!
By Jacob Levitt, MD, FAADVice Chairman, Program Director, and Associate Professor
The Mount Sinai Medical Center
Department of Dermatology
New York, NY
3/27/2017
2
Disclosures
• I have served on Advisory Boards for:• Amgen
• Janssen Biotech
• Genentech
• Medac
• Ranbaxy
• Pfizer
• From 2004-2010, I was a vice president and majority shareholder in Taro Pharmaceutical Industries Ltd.
3/27/2017
3
Acknowledgements
• Barrie Levitt, MD, FACC• author of: A Prescription for Success in Pharmaceuticals (in press)
• A book on how to run a pharmaceutical company
3/27/2017
7
U.S. Health Care Market
•2013 health care spend = $3.8 trillion (Forbes)
•$300 billion on Rx drugs annually (almost 10% of total spend) (IMS)
• > 80% of prescriptions written are filled generically (IMS)
3/27/2017
8
Increasing Prices in the Topical Market
• From 2008 to 2015, esp. after 2010
•Across generic topical suppliers• Actavis• Fougera (division of Sandoz – Novartis)• Perrigo• Taro (subsidiary of Sun Pharmaceuticals)• Teva Pharmaceuticals
3/27/2017
9
ARS: How much does generic clobetasolointment 60g cost out of pocket?
A. $10
B. $50
C. $100
D. $500
E. $1000
3/27/2017
10
ARS: How much does generic clobetasolointment 60g cost out of pocket?
A. $10
B. $50
C. $100
D. $500
E. $1000
3/27/2017
11
Actavis Clobetasol
$-
$50.00
$100.00
$150.00
$200.00
$250.00
$300.00
2008 2009 2010 2011 2012
Year Price2008 $ 20.21 2009 $ 20.52 2010 $ 20.42 2011 $ 7.22 2012 $ 281.37
1,292%
Price increase
cf: US Inflation Rate 10%
(2009 -2014)
Source: IMS data
3/27/2017
12
Taro Desoximetasone 0.05% cream
$-
$50.00
$100.00
$150.00
$200.00
$250.00
$300.00
$350.00
2008 2009 2010 2011 2012
Year Price2008 $ 7.26 2009 $ 9.45 2010 $ 17.61 2011 $ 81.90 2012 $ 328.60
4,426%
Price increase
cf: US Inflation Rate 10%
(2009 -2014)
Source: IMS data
3/27/2017
13
Fougera Desonide
$-
$20.00
$40.00
$60.00
$80.00
$100.00
$120.00
$140.00
2008 2009 2010 2011 2012
1,034%
Price increase
cf: US Inflation Rate 10%
(2009 -2014)
Year Price2008 $ 10.15 2009 $ 20.28 2010 $ 36.11 2011 $ 57.34 2012 $ 115.14
Source: IMS data
3/27/2017
14
Fougera Fluocinonide
961%
Price increase
cf: US Inflation Rate 10%
(2009 -2014)
Year Price2008 $ 5.16 2009 $ 4.25 2010 $ 4.44 2011 $ 13.94 2012 $ 54.72 $-
$10.00
$20.00
$30.00
$40.00
$50.00
$60.00
2008 2009 2010 2011 2012Source: IMS data
3/27/2017
16
ARSWhat percent of your prescriptions require Prior Authorizations (PAs)?
A.1%
B. 5%
C. 10%
D.20%
E. 30%
F. >50%
3/27/2017
17
ARS: For 1 day of practice, how many hours of employee work does a single physician generate in your office from prior authorizations?
A.1 hour
B. 5 hours
C. 10 hours
D.15 hours
E. 20 hours
3/27/2017
19
Examples Outside Topicals
• Generics: Between July 2013-14: • Pravastatin - 577% increase
• Divalproex – 797% increase
• Digoxin - 828% increase
• Doxycycline 4,400% ($3$135)!!! And that’s SMALL POTATOES!
• Brands: In 2012:• 11 of 12 oncology drugs cost > $100,000/year
• Prices doubled in past decade
• Imatinib (Gleevec) initially $30,000/year, now $90,000/year• For Novartis, revenue of $4.7 billion in 2012.
3/27/2017
20
More Participants
• AIDS• 1989: AZT cost $8,000/year… then the most expensive Rx drug in history
• Cystic Fibrosis• Ivacaftor (Kalydeco, Vertex Pharmaceuticals)
• Costs $311,000/year
• Hepatitis C• Ledipasvir/sofosbuvir (Harvoni) at $1125 per pill $189,000 for 24 weeks
• Sofosbuvir at $80,000 to $160,000 for a 3- to 6-month course• in Egypt and India, the drug company provides the full course of treatment for $900
• It seems that the U.S. healthcare participants subsidizes foreign healthcare participants
3/27/2017
22
Setting the Price of a Brand
• Recoup costs• R&D
• Manufacturing
• Prices of competing therapies
• Set price to take sales from market share of competitors
• What market will bear
3/27/2017
24
Generic Drugs
Legal Definition:
• Same active ingredient, dose, form, strength as the brand
• Same extent and rate of absorption (+/- 20%) or clinical bioequivalence
• Drug approved by FDA by means of an ANDA (Hatch Waxman Act)
Functional Definition:
• Formularies mandate generic price ≤ 80% brand price @ introduction
• Otherwise mandatory substitution is denied
3/27/2017
25
Standard Reasons For High Generic Prices…
• Competitors drop out Drug Shortages (none or single-source)
• Reasons for Dropouts & Barriers to New Competitors:• Raw material shortages• New FDA regulatory requirements for or delays in approval• Lack of product profitability• Technical difficulties with manufacturing• Problems with analytic methods• Product stability problems
•…Don’t Explain It• Present both before and after runaway price escalation
3/27/2017
27
ARS:Brand price is $1000/bottle. Your breakeven price is $50/bottle. You are the first generic to market. What would your price be?
A.$999
B. $900
C. $800
D.$500
E. $100
3/27/2017
28
ARS:You are now the second generic. Brand is $1000. First generic got license from the Brand and, in order to get on formularies, price at $800. Your breakeven price is $50/bottle. What will you charge?
A. $800
B. $790
C. $700
D. $600
E. $500
3/27/2017
29
ARS:Brand is $1000. First generic got license from the Brand and, in order to get on formularies, price at $800. Second generic came in at, say, $600. Your breakeven price is $50/bottle. You are now the third generic. What will you charge?
A. $800
B. $700
C. $600
D. $590
E. $500
F. $200
G. $51
3/27/2017
31
The Theory Underlying Generic Drugs
• Generic companies will price their products below the brand price
• Presumes competitors’ goal is to get 100% market share
• Anticipates competition via continual price reduction
• Mandates sacrifice of profit on the altar of sales (IRRATIONAL!)
• A cognitive bias we all share
3/27/2017
33
Two Problems with the Generic Price Theory
• Companies may focus on profit not market share
• Lower prices may not be passed on to the consumer
3/27/2017
35
Market Share (Units) vs. PriceMarket Share (Units) vs. Profit
($2.00)
$0.00
$2.00
$4.00
$6.00
$8.00
$10.00
$12.00
-$100,000
$0
$100,000
$200,000
$300,000
$400,000
$500,000
$600,000
$700,000
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Pri
ce
Pro
fit
Units in 000's
Profit Price
3/27/2017
37
Scenario I
• Brand sells at a high price
• Generic enters at 80% of brand
• Multiple generics fight for market share by lowering price• This may be irrational as we have learned
• Low equilibrium generic price results
• If one manufacturer were to raise his price…• No one would buy from him
• Customers will buy at the lowest price
3/27/2017
38
Scenario II
• Brand enters at high price
• Generics enter at 80%
• Multiple generics enter at high price hoping for a reasonable fraction of the market & good profit
• High equilibrium generic price
• What if one person dares to raise the price?• Everyone else raises theirs, market share stays the same, and profits
remain high
3/27/2017
39
Scenario I in Today’s Market
Scenario I was:
• Low equilibrium generic price
• What if one person raised the price?
• No one would buy from him, low price competitor keeps • the whole market
• Competitors would raise their price. • Everyone keeps their market share at a higher price.• Where is the ceiling?
• We are still exploring the ceiling.
3/27/2017
40
Is There Price Fixing In the Generic Marketplace?
• Pharma is inbred
• Many persons move from one company to another• E.g., Fougera/Sandoz, Perrigo, Taro, etc.
• Marketing philosophies move with the people • Not anti-trust collusion per se
3/27/2017
42
Health Insurance
• Before 1965:
• Patients paid out of pocket for drugs (small role of health insurance) keeps prices down
• Patients shopped from pharmacy to pharmacy for the best price
3/27/2017
43
Health Insurance• Before 1965:
• Patients paid out of pocket for drugs (small role of health insurance) keeps prices down
• Patients shopped from pharmacy to pharmacy for the best price
• After 1965:
• Medicaid, Medicare, and increasing availability of health insurance
• One party (physician) instructs a second party (patient) to purchase a prescription drug. A third party (government or insurance company)pays for it.
• Impairs negative feedback control by patients on prices
3/27/2017
44
Price Controls by Executive Order 11615 (1971)
•To prevent inflation, President Nixon froze prices for 90 days.
•Thereafter, in anticipation of another price freeze, manufacturers and middlemen maintained high invoice prices and used rebates to compete on price.
•Discounts from high invoice prices became the standard.
3/27/2017
45
Let’s compare two “perceptions” of pricing
• Traditional Pricing
• Mark-up culture
• General Public’s assumptions
• Actual Generic Drug Distribution
• Rebate culture
3/27/2017
46
Traditional Pricing
• Drug costs $3 to make.
• Manufacturer marks up drug to “middleman” for $30, earning $27.
• The middleman (distributor) marks up drug to patient for $50, earning $20.
3/27/2017
47
Who are the middlemen?
Manufacturer
Pharmacy Chains (CVS, Walgreen’s, Walmart)
Consumer
Manufacturer
Wholesalers (AmerisourceBergen, Cardinal Health, McKesson)
Pharmacy Chains (CVS, Walgreen’s, Walmart, Private Pharmacy, etc.)
Consumer
One Middleman Two Middlemen
3/27/2017
48
Contract Prices Hidden by Rebates
• Generic Drug X costs $3 to make
• Manufacturer invoices the drug to the middleman for $100
• Manufacturer marks down to a confidential contract price with the middleman of $30
• Manufacturer pays middleman a $70 REBATE to get to the contract price
• Middleman can mark up drug to patient for $120
3/27/2017
49
Patient Perspective
• Manufacturer appears to be the bad guy since the consumer pays $120
• Manufacturer makes same profit, i.e., $27, either way
• Middleman makes $90
keeps markup ($20) + the rebate ($70)
on the back of the consumer
3/27/2017
50
So what have we revealed...
1. Generic pricing theory that lower price means more market share means more profit is a cognitive bias that gives us unreasonable expectations from rational profit seekers in a capitalist market. The rational behavior for a manufacturer is to raise prices for optimal profit rather than lower prices to take market share.
3/27/2017
52
3. At the same time, inflationary pressures resulted in the evolution of an invoice system to distributors with opaque rebates and high end-consumer prices. In the absence of negative feedback, prices rose.
3/27/2017
53
In Summary…
• Competitors are not lowering prices
• Rebates in the supply chain are not passed on to consumers
DRUG PRICES ARE HIGH
Q.E.D.
3/27/2017
54
Some solutions?
• Price transparency
• Make it illegal to rebate off of high WAC pricing
• Lower barriers to generic competition
• Government subsidies to drug developers but require pricing caps after costs plus some reasonable profit is achieved
• Force pharmacies to stock the lowest priced drug in the market
• Cap mark up beyond a certain percentage